As More Leading Doctors Oppose Avandia, Will Indian Regulators Propose A Ban?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Leading Indian doctors have begun speaking out against GlaxoSmithKline's anti-diabetes brand Avandia (rosiglitazone) - branded as Windia in the Indian market - after U.S.FDA restricted the drug's use and European regulatory authorities ordered a complete withdrawal of the medicine from the market
You may also be interested in...
As Doctors Mount Pressure On Government, India Bans Diabetes Drug Rosiglitazone In Line With EU Action
MUMBAI - The Drug Controller General of India has banned use of anti-diabetes agent rosiglitazone following a meeting of an expert committee called by the Ministry of Health and Family Welfare to study the safety issues related to the drug
As Doctors Mount Pressure On Government, India Bans Diabetes Drug Rosiglitazone In Line With EU Action
MUMBAI - The Drug Controller General of India has banned use of anti-diabetes agent rosiglitazone following a meeting of an expert committee called by the Ministry of Health and Family Welfare to study the safety issues related to the drug
China's Drug Regulators Issue Warning On Use Of Avandia While Debating Suspension Vs. Restricted Use
SHANGHAI - China's State FDA issued a warning Sept. 25 on the potential cardiovascular risk of using drugs containing rosiglitazone and told the public that the agency is organizing a committee of experts to evaluate the benefits and risks of rosiglitazone drugs, including GlaxoSmithKline's Avandia (rosiglitazone), Avandamet (metformin and rosiglitazone) and generics